No April Fool's Joke: MannKind's Critical Vote

Shares of MannKind (NASDAQ: MNKD  ) took more than a 5% haircut on Friday as briefing documents came out for its upcoming FDA advisory committee meeting on Tuesday. The documents are a mixed bag, which should make for a very interesting debate in Tuesday's meeting. The drug, an inhaled form of insulin called Afrezza, had efficacy that looked good for type 2 diabetes, but wasn't as convincing on type 1. There are also potential safety concerns, including an imbalance of lung cancer cases in the drug's cohort which could be associated with inhaled insulin as a drug class. A similar small imbalance, dogged a predecessor product, Pfizer's (NYSE: PFE  ) Exhubera.

There is a great deal of investor optimism around the sales potential of Afrezza, as an alternative to needles. Investors see Novo Nordisk's (NYSE: NVO  ) Novalog and Eli Lilly's (NYSE: LLY  ) Humalog's roughly $1.5 billion each in U.S. sales last year and think it can capture a significant portion, possibly as much as a quarter of that market. However, MannKind's high valuation and significant downside risk if Afrezza is rejected, makes this a stock even serious biotech investors with a Mount Everest-high risk tolerance should probably watch from sidelines. 

In this video, Motley Fool health-care analyst David Williamson looks at MannKind today, ahead of the advisory committee's meeting. The vote could greatly affect the outcome of an FDA decision. David discusses the potential for the drug on the market, and how MannKind would be affected by an FDA rejection.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology  behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and it's ability to make life-changing medical solutions never thought possible.  To learn how you can invest in this unbelievable new technology, click here now to see our free report.


Read/Post Comments (6) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2895822, ~/Articles/ArticleHandler.aspx, 9/20/2014 10:12:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement